| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Acamprosate calcium (JAN/USAN); Campral (TN); Regtect (TN) | ||||||||||
| Product | |||||||||||
| Generic | ACAMPROSATE CALCIUM (American Health Packaging), ACAMPROSATE CALCIUM (AvKARE), ACAMPROSATE CALCIUM (Cadila Healthcare Limited), ACAMPROSATE CALCIUM (Glenmark Pharmaceuticals), ACAMPROSATE CALCIUM (Major Pharmaceuticals), ACAMPROSATE CALCIUM (Teva Pharmaceuticals USA), ACAMPROSATE CALCIUM (Zydus Pharmaceuticals (USA)), ACAMPROSATE CALCIUM (Mylan Pharmaceuticals) | ||||||||||
| Formula | (C5H10NO4S)2. Ca | ||||||||||
| Exact mass | 400.0287 | ||||||||||
| Mol weight | 400.4824 | ||||||||||
| Structure |  | ||||||||||
| Class | Neuropsychiatric agent DG01498 NMDA receptor antagonist | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antialcohol dependence, NMDA receptor antagonist | ||||||||||
| Disease | Alcohol dependence [DS:H01611] | ||||||||||
| Comment | Treatment of alcohol dependency | ||||||||||
| Target | GRIN (NMDAR) [HSA:2902 2903 2904 2905 2906] [KO:K05208 K05209 K05210 K05211 K05212] | ||||||||||
| Pathway |
| ||||||||||
| Interaction | |||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N07 OTHER NERVOUS SYSTEM DRUGS N07B DRUGS USED IN ADDICTIVE DISORDERS N07BB Drugs used in alcohol dependence N07BB03 Acamprosate D02780 Acamprosate calcium (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Anti-Addiction/Substance Abuse Treatment Agents Alcohol Deterrents/Anti-craving Acamprosate D02780 Acamprosate calcium (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 119 Miscellaneous 1190 Miscellaneous D02780 Acamprosate calcium (JAN/USAN) Drug groups [BR:br08330] Neuropsychiatric agent DG01498 NMDA receptor antagonist DG00996 Acamprosate D02780 Acamprosate calcium Target-based classification of drugs [BR:br08310] Ion channels Ligand-gated ion channels Glutamate (ionotropic), NMDA GRIN (NMDAR) D02780 Acamprosate calcium (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D02780 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D02780 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D02780 Drug groups [BR:br08330] Neuropsychiatric agent DG01498 NMDA receptor antagonist DG00996 Acamprosate | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 23 1 C1a C 21.6233 -20.9826 2 C5a C 22.8217 -21.6744 3 N1b N 24.0200 -20.9826 4 C1b C 25.2183 -21.6744 5 C1b C 26.4166 -20.9826 6 C1b C 27.6150 -21.6744 7 S4a S 28.8134 -20.9826 8 O5a O 22.8217 -23.0582 9 O1d O 30.0258 -21.6827 #- 10 O1d O 30.0258 -20.2826 11 O1d O 27.6009 -20.2826 12 Z Ca 34.4228 -22.0203 #2+ 13 C1a C 21.6233 -20.9826 14 C5a C 22.8217 -21.6744 15 N1b N 24.0200 -20.9826 16 C1b C 25.2183 -21.6744 17 C1b C 26.4166 -20.9826 18 C1b C 27.6150 -21.6744 19 S4a S 28.8134 -20.9826 20 O1d O 30.0258 -21.6827 #- 21 O1d O 30.0258 -20.2826 22 O1d O 27.6009 -20.2826 23 O5a O 22.8217 -23.0582 BOND 20 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 6 7 1 7 2 8 2 8 7 9 1 9 7 10 2 10 7 11 2 11 13 14 1 12 14 15 1 13 15 16 1 14 16 17 1 15 17 18 1 16 18 19 1 17 14 23 2 18 19 20 1 19 19 21 2 20 19 22 2 BRACKET 1 19.7400 -24.0100 19.7400 -18.6200 1 31.0800 -18.6200 31.0800 -24.0100 1 2 ORIGINAL 1 1 2 3 4 5 6 7 9 10 11 8 REPEAT 1 13 14 15 16 17 18 19 20 21 22 23 |